Unitree Robotics Reports 270% YoY Net Profit Growth to 387 Million Yuan in First Three Quarters
nashnova research
Unitree Robotics reported attributable net profit of RMB 387 million, up 270% year-on-year for the first three quarters — but recurring-basis net profit actually fell 19%, revealing the gain came from one-off items, not the core business.
How fast is revenue growing?
First-three-quarter revenue hit RMB 1.817 billion, up 55.71% year-on-year.
Q3 alone delivered RMB 665 million, with growth accelerating to 69.93%.
This means → products are selling well; the pressure is entirely on the profit line, not the top line.
Net profit surged 270% — why the asterisk?
Attributable net profit reached RMB 387 million, up 270.54% — a headline-grabbing number.
Yet recurring net profit — stripping out one-off gains — came in at RMB 349 million, down 18.78%.
In plain terms = remove non-recurring items like government subsidies and investment gains, and the company actually earned less from its core operations than a year ago. The 270% headline does not hold up on a recurring basis.
What did Q3 alone look like?
Q3 attributable net profit was RMB 113 million, down 17.37%; recurring net profit was RMB 105 million, down 17.42%.
Revenue growth accelerated while profits shrank — the divergence is sharper at a single-quarter level.
This reflects a phase where Unitree is scaling fast but costs and expenses are scaling faster; top-line expansion has not yet translated into stronger profitability.
What does this mean for investors?
The divergence between attributable and recurring net profit is the key signal: one-off gains are not repeatable, and without a similar windfall next period, profit growth will decelerate sharply.
This means → investors should look past the "270%" headline and track the recurring profit trend — that is the real measure of the business's earning power.
Open questions ahead: where cost pressure is coming from (R&D? channel expansion? supply chain?) and what exactly the non-recurring items consist of.
市场有风险，内容仅供研究参考，不构成投资建议。